Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. ACN
9. COHR
10. META

Go back to Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
Stratcomm Media, Ltd. (NASDAQ: SMMT) Delayed: 16.90 -0.95 (5.32%)
Previous Close $17.85    52 Week High $19.75 
Open $18.40    52 Week Low $4.26 
Day High $18.42    P/E N/A 
Day Low $16.64    EPS $0.00 
Volume 5,780,327